Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Chaige Tui Re Oral Liquid is a Traditional Chinese Medicine (TCM) botanical product developed by Suzhou Yusen New Drug Development Co., Ltd. It is specifically formulated for pediatric use to treat acute upper respiratory tract infections and the common cold, particularly those characterized by the wind-heat pattern in TCM theory. The name Chaige indicates the inclusion of Radix Bupleuri (Chai Hu) and Radix Puerariae (Ge Gen), which are known for their antipyretic, anti-inflammatory, and analgesic properties. The drug is administered as an oral liquid and has been studied in Phase 2 clinical trials in China to evaluate its safety and efficacy in reducing fever and other respiratory symptoms in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Chaige Tui Re Oral Liquid.